Clinical trials: Arthritis;Inflammatory
Myositis, Inflammatory
Novel PET Radioligand as an Inflammatory Biomarker in Musculoskeletal Conditions
Background: Inflammation plays a significant role in various disorders that involve neurodegeneration or autoimmune reaction as one of their mechanisms. PET scans can help detect inflammation.
- Conditions
- Myositis, Inflammatory, Rheumatoid Arthritis, Healthy Volunteers
- Trial name
- NCT03912428
- Testing
- 11C-MC1, Celecoxib, [11C]ER176
- Where
- United States
- Volunteers
- 31 people
- Sponsor
- National Institute of Mental Health (NIMH)
Spondylitis, Ankylosing
A Two-Part 26-Week Study of Etoricoxib as Treatment for Ankylosing Spondylitis (AS) (MK-0663-108)
The purpose of the study is to evaluate the efficacy and tolerability of two doses of etoricoxib compared to naproxen in the treatment of ankylosing spondylitis (AS).
- Trial name
- NCT01208207
- Testing
- Part I - etoricoxib 60 mg, Part I - etoricoxib 90 mg, Part I- naproxen 1000 mg
- Volunteers
- 1,015 people
- Sponsor
- Organon and Co
Arthritis, Juvenile
A Study to Evaluate the Pharmacokinetics, Efficacy and Safety of Intravenous Golimumab in Pediatric Participants With Active Polyarticular Course Juvenile Idiopathic Arthritis Despite Methotrexate Therapy
The purpose of this study is to evaluate the pharmacokinetics (the study of the way a drug enters and leaves the blood and tissues over time) of golimumab administered intravenously (IV) to pediatric participants with…
- Trial name
- GO-VIVA (NCT02277444)
- Testing
- Golimumab, Methotrexate
- Where
- 38 sites in United States, Argentina and 7 more
- Volunteers
- 130 people
- Sponsor
- Janssen Research & Development, LLC
Rheumatoid Arthritis
Study To Assess The Efficacy And Safety Of Pf-06651600 In Subjects With Rheumatoid Arthritis With An Inadequate Response To Methotrexate
This is an 8 week study to assess the efficacy and safety profile of PF-06651600 in seropositive subjects with rheumatoid arthritis with an inadequate response to methotrexate (up to approximately 50% of subjects may also have…
- Trial name
- NCT02969044
- Testing
- PF-06651600
- Where
- 30 sites in United States, Bulgaria and 7 more
- Volunteers
- 70 people
- Sponsor
- Pfizer
Osteoarthritis, Degenerative
A Pilot Trial to Assess Low-Intensity Ultrasound in Osteoarthritis
The purpose of this exploratory trial is to investigate whether PLIUS is potentially effective as a disease and symptom modifying intervention in patients with early knee OA.
- Trial name
- PLUS+OA (NCT02034409)
- Testing
- Pulsed Low Intensity Ultrasound
- Where
- 3 sites in United States
- Volunteers
- 140 people
- Sponsor
- VA Office of Research and Development
Rheumatoid Arthritis
A Study of Combination Treatment With MabThera (Rituximab) and RoActemra (Tocilizumab) Versus RoActemra in Patients With Rheumatoid Arthritis With an Incomplete Response to Methotrexate
This 2 part study will investigate the safety, tolerability and efficacy of MabT hera in combination with RoActemra in patients with active rheumatoid arthritis despite a stable dose of methotrexate.
- Trial name
- NCT00845832
- Testing
- rituximab [MabThera/Rituxan], tocilizumab [RoActemra/Actemra]
- Where
- 24 sites in France, Germany and 6 more
- Volunteers
- 24 people
- Sponsor
- Hoffmann-La Roche
Knee Osteoarthritis
Fasitibant Intra-articular Injection in Patients With Symptomatic Osteoarthritis of the Knee
This study is designed as a double-blind, randomised, placebo-controlled, four parallel arm, dose-finding study, to be conducted in approximately 26 sites, to evaluate the efficacy, safety, tolerability, and pharmacokinetics of…
- Trial name
- ALBATROSS-3 (NCT02205814)
- Testing
- Fasitibant- low dose, Fasitibant- intermediate dose, Fasitibant- high dose
- Where
- 25 sites in United States, Czechia and 2 more
- Volunteers
- 436 people
- Sponsor
- Menarini Group
Rheumatoid Arthritis
A Study of MabThera/Rituxan (Rituximab) in Combination With Methotrexate in Patients With Rheumatoid Arthritis and Inadequate Response to DMARD Therapy
This study will evaluate the efficacy and safety of MabThera/Rituxan plus methotrexate in patients with active rheumatoid arthritis who have had an inadequate response to at least 1 DMARD treatment.
- Trial name
- NCT02006706
- Testing
- rituximab [MabThera/Rituxan], methotrexate, methylprednisolone
- Where
- 3 sites in Serbia
- Volunteers
- 15 people
- Sponsor
- Hoffmann-La Roche
Osteoarthritis of the Hip
Total Hip Arthroplasty (THA) Surgical Techniques Comparing the Direct Anterior Approach to the Posterior Approach
The purpose of this study is to compare the short term effectiveness and return to function of subjects undergoing primary Total Hip Arthroplasty using an Anterior Approach (incision on the front part of the hip joint) versus…
- Trial name
- NCT01807104
- Testing
- Anterior Approach / Posterior Approach, Anterior versus Posterior Approach for total hip replacement
- Where
- United States
- Volunteers
- 87 people, healthy volunteers welcome
- Sponsor
- Barrett, William, M.D.
Rheumatoid Arthritis
RESTART C0168Z05 Rheumatoid Arthritis Study
The purpose of this study is to assess the effectiveness of treatment in patients with active rheumatoid arthritis who are having an inadequate response to at least 3 months of treatment with etanercept or adalimumab in addition…
- Trial name
- NCT00714493
- Testing
- Infliximab
- Where
- 76 sites in United States, Austria and 8 more
- Volunteers
- 203 people
- Sponsor
- Centocor Ortho Biotech Services, L.L.C.
Osteoarthritis, Knee
Senolytic Drugs Attenuate Osteoarthritis-Related Articular Cartilage Degeneration: A Clinical Trial
Phase I/II randomized, double-blind, placebo-controlled clinical trial to test the safety and efficacy of Fisetin for treating mild to moderate osteoarthritis
- Trial name
- NCT04210986
- Testing
- Fisetin
- Where
- United States
- Volunteers
- 75 people
- Sponsor
- Steadman Philippon Research Institute
Osteoarthritis of the Knee
Phase IIa, Randomized, Double Blinded, Placebo Controlled, Dose Finding Study for TLC599 in OA Patients
This trial is a Phase IIa, Randomized, Double blinded, Placebo controlled, Dose finding Study to investigate the safety and efficacy of TLC599 in subjects with osteoarthritis of the knee.
- Trial name
- NCT03005873
- Testing
- TLC599 LD group, Normal Saline, TLC599 HD group
- Where
- 13 sites in Australia, Taiwan
- Volunteers
- 76 people
- Sponsor
- Taiwan Liposome Company
Joint Disease, Rheumatoid Arthritis
an On-demand Program to EmpoweR Active Self-management (OPERAS)
Self-management is a key component of successful chronic disease management and patients can benefit from learning about how daily activities and treatments relate to their symptoms and health status on an ongoing basis.
- Trial name
- OPERAS (NCT03404245)
- Testing
- Education, Fitbit/self-management app, physiotherapist counselling., Same intervention with a 6 month delay
- Where
- Canada
- Volunteers
- 132 people
- Sponsor
- University of British Columbia
Osteoarthritis, Rheumatoid Arthritis
The 3DKnee™ System: A Post-Market Study
The purpose of this study is to evaluate the survivorship and efficacy of the Encore 3DKnee™ system in a group of patients who will receive the 3DKnee™ as a primary (first) orthopedic implant in the knee.
- Conditions
- Osteoarthritis, Rheumatoid Arthritis, Post Traumatic Arthritis, Varus Deformity
- Trial name
- NCT00764673
- Testing
- 3DKnee
- Where
- United States
- Volunteers
- 71 people
- Sponsor
- Encore Medical, L.P.
Systemic Juvenile Idiopathic Arthritis
An Open-label Extension Study of Canakinumab in Patients With Systemic Juvenile Idiopathic Arthritis and Active Systemic Manifestations Manifestations and Response Characterization Study in Canakinumab Treatment-naïve Patients With Active SJIA With and Without Fever.
This open-label extension study will permit patients with Systemic Juvenile Idiopathic Arthritis (SJIA) who previously were responsive to treatment with canakinumab and canakinumab treatment-naïve patients with active SJIA with…
- Trial name
- β-SPECIFIC 3 (NCT00891046)
- Testing
- Canakinumab
- Where
- 73 sites in United States, Argentina and 19 more
- Volunteers
- 270 people
- Sponsor
- Novartis Pharmaceuticals
Osteoarthritis, Knee
TSolution One® Total Knee Arthroplasty
The goal of this prospective, non-randomized, multicenter clinical trial is to determine whether robotic-assisted total knee arthroplasty performed with TSolution One® System is safe and effective for use as an alternative to the…
- Trial name
- NCT03017261
- Testing
- TSolution One®
- Where
- 6 sites in United States
- Volunteers
- 115 people
- Sponsor
- Think Surgical Inc.
Ankylosing Spondyloarthritis
Study of Efficacy and Safety of Secukinumab in Patients With Ankylosing Spondylitis
The purpose of this trial is to demonstrate the clinical efficacy at week 16; and to demonstrate safety and tolerability of secukinumab compared to placebo in patients with ankylosing spondylitis at week 16 and long term safety…
- Trial name
- NCT02896127
- Testing
- Secukinumab
- Where
- 44 sites in China, Czechia and 2 more
- Volunteers
- 458 people
- Sponsor
- Novartis Pharmaceuticals
Rheumatoid Arthritis
Efficacy, Safety and Tolerability of ACZ885 in Patients With Active Rheumatoid Arthritis
The 12-week core study was designed to evaluate risk-benefit of three subcutaneous dose regimens of ACZ885, added on to stable methotrexate (MTX) therapy (greater than or equal to 7.5 mg/week), compared to placebo in patients…
- Trial name
- NCT00424346
- Testing
- Canakinumab
- Where
- 17 sites in United States, Austria and 4 more
- Volunteers
- 274 people
- Sponsor
- Novartis
Osteoarthritis
The Use of Evicel to Reduce Blood Loss in Total Knee Replacement Surgery
Application of "Evicel" hemostatic matrix during operation for unilateral total knee replacement surgery (TKA) will result in decreased bleeding and postoperative drain output, a reduction in transfusion requirements, and less…
- Trial name
- NCT01235715
- Testing
- Evicel fibrin sealant
- Where
- United States
- Volunteers
- 200 people
- Sponsor
- Hospital for Special Surgery, New York
Arthritis
PyroTITAN Humeral Resurfacing Arthroplasty (HRA)
The study is designed as a single center, post-market, non-randomized, open-label, observational clinical study with retrospective and prospective enrollment to evaluate the 2-year post implantation survivorship of the PyroTITAN™…
- Trial name
- HRA (NCT02983292)
- Testing
- PyroTITAN™ HRA
- Where
- Australia
- Volunteers
- 137 people
- Sponsor
- Smith & Nephew, Inc.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.